Michel Weber

ORCID: 0000-0001-5884-1177
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Retinal Diseases and Treatments
  • Retinal and Optic Conditions
  • Ocular Diseases and Behçet’s Syndrome
  • Glaucoma and retinal disorders
  • Retinal Imaging and Analysis
  • Retinal Development and Disorders
  • Intraocular Surgery and Lenses
  • Retinal and Macular Surgery
  • Virus-based gene therapy research
  • Ocular Infections and Treatments
  • Ophthalmology and Visual Impairment Studies
  • Systemic Lupus Erythematosus Research
  • Retinopathy of Prematurity Studies
  • Vascular Malformations Diagnosis and Treatment
  • Herpesvirus Infections and Treatments
  • CRISPR and Genetic Engineering
  • Nephrotoxicity and Medicinal Plants
  • Cerebral Venous Sinus Thrombosis
  • Corneal surgery and disorders
  • Traumatic Ocular and Foreign Body Injuries
  • Ocular Oncology and Treatments
  • Ophthalmology and Visual Health Research
  • Photoreceptor and optogenetics research
  • Neuroscience and Neural Engineering
  • Hepatitis B Virus Studies

Centre Hospitalier Universitaire de Nantes
2015-2025

Nantes Université
2014-2025

Centre d'Investigation Clinique de Nantes
1999-2024

Inserm
1997-2024

Institut de Recherche Mathématique Avancée
2024

Gene Therapy Laboratory
2006-2023

Translational Research in Gene Therapy
2020-2023

Triemli Hospital
2004-2023

Université de Rouen Normandie
2020

Centre Hospitalier Universitaire de Tours
2020

Arshad M. Khanani Sunil Patel Giovanni Staurenghi Ramin Tadayoni Carl J. Danzig and 95 more David Eichenbaum Jason Hsu Charles C. Wykoff Jeffrey S. Heier David R. Lally Jordi Monés Jared S. Nielsen Veeral Sheth Peter K. Kaiser Julie Clark Liansheng Zhu Hersh Patel Justin Tang Dhaval Desai Glenn J. Jaffe Arturo Alezzandrini A Francone Joaquín Bafalluy Silvina Bainttein José D. Luna Mario Saravia Matko Vidosevich Carlos Zeolite Federico Furno Sola Andrew Chang Elisa E. Cornish Thanh N. Nguyen Oliver Findl Anton Haas Martina Kralinger Stefan Sacu Laurence Postelmans Michel Eid Farah Maurício Maia Márcio Bittar Nehemy Fareed Ali Michael H. Brent Michael Dollin John R. Gonder Amin Kherani Andrew Merkur Raman Tuli Monica Marie Lopera Francisco J. Rodríguez Mario Bradvica Jan Ernest Kuldar Kalijurand Kai Noor Yves Cohen Catherine Creuzot‐Garcher F. De Bats François Devin Catherine Français-Maury Laurent Kodjikian Jean François Korobelnik Y. Le Mer M. Quaranta El Maftouhi Sam Razavi Eric H. Souied Ramin Tadayoni Michel Weber Nicole Eter Nicolas Feltgen Salvatore Grisanti Peter Walter Raffael Liegl Katrin Lorenz Georg Spital Siegfried Priglinger Martin S. Spitzer Michael Völker Tim U. Krohne Claudia Jochmann Chris P. Lohmann Carsten Framme Ágnes Kerényi András Papp András Seres Edit Tóth‐Molnár Alexis Tsorbatzoglou A VAJAS Balázs Varsányi Gábor Vogt Asaf Bar Eva Eting David Hauser Jamie Levy Nurit Mathalone Haia Morori-Katz Irit Rosenblatt Shiri Soudry-Zayit Omert Trivizky Francesco Bandello Antonio P. Ciardella Michele Figus

10.1016/s0140-6736(23)01583-0 article EN The Lancet 2023-09-08

We previously described chimeric recombinant adeno-associated virus (rAAV) vectors 2/4 and 2/5 as the most efficient in rat retina. now characterize these two carrying CMV.gfp genome following subretinal injection Wistar rat, beagle dog, cynomolgus macaque. Both serotypes displayed stable GFP expression for duration of experiment (6 months) all three animal models. Similar to AAV-2 serotype, AAV-2/5 transduced both RPE photoreceptor cells, with higher level transduction photoreceptors,...

10.1016/s1525-0016(03)00098-4 article EN cc-by-nc-nd Molecular Therapy 2003-05-01

To present the safety and efficacy of intravitreal implants releasing 0.2 μg/day fluocinolone acetonide (FAc) in patients with chronic versus nonchronic diabetic macular edema (DME). assess ocular characteristics, anatomic changes, re-treatment ancillary therapies that may explain differential treatment effect seen FAc DME. An overall benefit-to-risk assessment for 0.2-μg/day 0.5-μg/day doses has been reported previously. Preplanned subgroup analysis (duration diagnosis, ≥3 years) <3 DME...

10.1016/j.ophtha.2014.04.019 article EN cc-by-nc-nd Ophthalmology 2014-06-16

To assess the efficacy and safety of adalimumab on uveitis in patients with early onset, chronic, juvenile idiopathic arthritis (JIA)-associated or anterior an inadequate response to topical steroids methotrexate (MTX).Patients aged 4 years more ocular inflammation quantified by laser flare photometry (LFP) ≥30 photon units/ms were double-blindly randomised (1:1) 2 groups, one treated placebo subcutaneously at a dose 24 mg/m2 <13 years, 40 mg others, every other week. The primary outcome was...

10.1136/annrheumdis-2017-212089 article EN Annals of the Rheumatic Diseases 2017-12-23

The aim of this study was the evaluation safety and efficacy unilateral subretinal injection adeno-associated vector (AAV) serotypes 2 4 (AAV2/4) RPE65-RPE65 in patients with Leber congenital amaurosis (LCA) associated RPE65 gene deficiency. We evaluated ocular general tolerance visual function up to 1 year after administration most severely affected eye nine retinal degeneration mutations gene. Patients received either low (1.22 × 1010 genomes [vg]) or high (between 3.27 4.8 vg) doses. An...

10.1016/j.ymthe.2017.09.014 article EN cc-by-nc-nd Molecular Therapy 2017-09-20

<h3>Aim:</h3> To describe the types and location of choroidal neovascularisation (CNV) in exudative age-related macular degeneration (AMD), including vascularised pigment epithelial detatchments (PED), most recently described subtypes, such as retinal anasmostosis, also termed "retinal angiomatous proliferation" (RAP). <h3>Methods:</h3> Prospective multicentre consecutive descriptive case series. A total 207 cases newly diagnosed AMD undergoing fluorescein angiography (FA) were recruited by...

10.1136/bjo.2007.115501 article EN British Journal of Ophthalmology 2007-03-23

<h3>Aim</h3> To assess the effectiveness of intravitreal dexamethasone implants for treating postsurgical macular oedema (PSMO) including Irvine–Gass syndrome and determining predictive factors treatment response. <h3>Methods</h3> Descriptive, observational, retrospective, consecutive, uncontrolled, multicentre, national case series. One hundred patients were included between April 2011 June 2014, with a minimum 1-year follow-up. Patients received implant 0.7 mg at baseline. Clinical...

10.1136/bjophthalmol-2016-308544 article EN British Journal of Ophthalmology 2016-05-17

To present interim descriptive insights from the OCTOPUS and SWIFT studies on incidence, clinical features, management, outcomes of intraocular inflammation (IOI), vasculitis, occlusive vasculitis with brolucizumab treatment (Beovu, Novartis) in patients neovascular age-related macular degeneration (nAMD) who were anti-VEGF naive or pretreated anti-VEGFs (ranibizumab aflibercept).OCTOPUS (NCT04239027) (NCT04264819) are prospective phase IIIb single-arm, open-label, multicenter assessing...

10.1016/j.oret.2023.06.009 article EN cc-by-nc-nd Ophthalmology Retina 2023-06-19

We recently evidenced a dramatic enrichment for T cells reactive against Epstein-Barr virus (EBV) within inflamed joints of two rheumatoid arthritis patients. To assess the generality this phenomenon and its relevance to autoimmunity, we studied responses CD8 from patients with either acute or chronic inflammatory diseases (rheumatoid arthritis: n = 18, ankylosing spondylitis: 5, psoriatic 4, Reiter's syndrome: 3, arthrosis: 2, uveitis: multiple sclerosis: encephalitis: 1) viral proteins...

10.1002/(sici)1521-4141(199903)29:03<973::aid-immu973>3.0.co;2-p article EN European Journal of Immunology 1999-03-01

Adeno-associated viral gene therapy has shown promise for the treatment of inherited and acquired retinal disorders. In most applications, regulation expression is a critical concern both safety efficacy. The purpose our study was to evaluate ability tetracycline-regulatable system establish long-term transgene in retina nonhuman primates. Three rAAV vectors expressing tetracycline-dependent transactivator (rtTA) under control either ubiquitous CAG promoter or specific RPE65...

10.1016/j.ymthe.2005.12.001 article EN cc-by-nc-nd Molecular Therapy 2006-01-27

Gene transfer to the retina using recombinant adeno-associated viral (rAAV) vectors has proven be an effective option for treatment of retinal degenerative diseases in several animal models and recently advanced into clinical trials humans. To date, intracellular trafficking AAV subsequent capsid degradation been studied only vitro, but fate particles transduced cells following subretinal injection yet elucidated. Using electron microscopy western blot, we analyzed retinas one primate four...

10.1038/mt.2008.283 article EN cc-by-nc-nd Molecular Therapy 2008-12-23

Recombinant adeno-associated virus (rAAV) vectors are among the most efficient gene delivery vehicles for transfer to retina. This study evaluates behavior of rAAV8 serotype vector with regard intraocular in rats and dogs. Subretinal an AAV2/8.gfp results retinal pigment epithelium (RPE), photoreceptors and, surprisingly, cells inner nuclear layer as well ganglion cells. Most importantly, dogs, also occurred distal injection site neurons lateral geniculate nucleus brain. Because green...

10.1038/mt.2008.41 article EN cc-by-nc-nd Molecular Therapy 2008-04-03

For the development of new therapies, proof-of-concept studies in large animal models that share clinical features with their human counterparts represent a pivotal step. inherited retinal dystrophies primarily involving photoreceptor cells, efficacy gene therapy has been demonstrated canine stationary cone and progressive rod–cone but not cone–rod dystrophies, another important cause blindness. To address last issue, we evaluated retinitis pigmentosa GTPase regulator interacting protein 1...

10.1038/mt.2013.232 article EN cc-by-nc-nd Molecular Therapy 2013-10-04

Refractive error (RE), particularly myopia, is the first cause of visual impairment throughout world. This study aimed to depict prevalence myopia in a multicentric series French individuals.This cross-sectional analysis was carried out between January 2012 and November 2013 eye clinics dedicated REs. Data collection included age, gender, best-corrected acuity, RE, any relevant medical history involving laser refractive surgery cataract surgery. Exclusion criteria consisted monophthalm...

10.1097/md.0000000000001976 article EN cc-by-nc Medicine 2015-11-01

Defects in the β subunit of rod cGMP phosphodiesterase 6 (PDE6β) are associated with autosomal recessive retinitis pigmentosa (RP), a childhood blinding disease early retinal degeneration and vision loss. To date, there is no treatment for this pathology. The aim preclinical study was to test recombinant adeno-associated virus (AAV)-mediated gene addition therapy rod-cone dysplasia type 1 (rcd1) dog, large animal model naturally occurring PDE6β deficiency that strongly resembles human A...

10.1038/mt.2012.134 article EN cc-by-nc-nd Molecular Therapy 2012-07-24

Purpose: To analyze retinal perfusion (RP) using ultrawide-field fluorescein angiography (UWFA) and optical coherence tomography (OCTA), in patients with central vein occlusion (CRVO) treated by intravitreal injection of aflibercept. Methods: Single-arm, multicenter, prospective, observational study. Treatment-naive eyes CRVO initiated therapy UWFA correction projection distortion OCTA were performed at baseline (M0), M3, M12, M24. Results: Fifty-six included. Visual acuity improved 16 ETDRS...

10.1097/iae.0000000000004425 article EN cc-by-nc-nd Retina 2025-02-05

To explore the predictability of changes in neovascularization morphology on optical coherence tomography angiography (OCTA) relation to exudative activity structural (OCT) eyes with neovascular age-related macular degeneration (nAMD) treated ranibizumab 0.5 mg. Eighty-five 85 patients nAMD, diagnosed less than 1 year prior study entry and mg, were included this longitudinal, prospective study. Included had no feature at inclusion mg a PRN regimen for following 9 months. At each visit OCT...

10.1097/iae.0000000000004444 article EN Retina 2025-02-26

The purpose of our study was to evaluate the biodistribution rAAV vectors following subretinal or intravitreal injection. In rats, we performed injections rAAV-2/2.CMV.gfp. large animals, rAAV-2/4.CMV.gfp rAAV-2/5.CMV.gfp delivered into space while rAAV-2/2.CMV.gfp either vitreous. euthanized undertook a complete necropsy. animals maintained alive, collected blood and tissue samples from submandibular lymph node, liver, gonads. We analyzed total DNA, extracted various peripheral mononuclear...

10.1016/j.ymthe.2004.09.022 article EN cc-by-nc-nd Molecular Therapy 2004-12-16

Abstract Purpose Diabetic macular oedema (DMO) is a leading cause of blindness in working-age adults. Slow-release, nonbioerodible fluocinolone acetonide (FAc) implants have shown efficacy the treatment DMO; however, National Institute for Health and Care Excellence recommends that FAc should be used patients with chronic DMO considered insufficiently responsive to other available therapies only if eye treated pseudophakic. The goal this analysis was examine outcomes phakic who received 0.2...

10.1038/eye.2015.98 article EN cc-by Eye 2015-06-26

The aim of the study was to assess microperimetric consequences active internal limiting membrane (ILM) peeling during idiopathic epimacular (IEMM) surgery.This retrospective monocentric included 32 eyes 31 consecutive patients who underwent IEMM surgery. Internal integrity assessed by ILM Blue staining after removal: spontaneous (Group S) or A). Preprocedure and postprocedure (1 6 months) examinations were performed using visual acuity determination, spectral domain optical coherence...

10.1097/iae.0000000000001179 article EN Retina 2016-07-16
Coming Soon ...